IP Library › Granted Patent US 12,709,602
Granted Patent B2
US 12,709,602 · App. 18/123,102 · Granted Aug 18, 2026

Intermediates for making derivatives of substituted morpholines

Inventors: Yanjun Sun (Kendall Park, NJ); Bhaskara Rao Nallaganchu (Hillsborough, NJ); Gary L. Olson (Mountainside, NJ)
Assignee: Supernus Pharmaceuticals, Inc.
C07D265/30B01J31/0239B01J2231/347B01J2231/348B01J2531/002C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,602
App. No.
18/123,102
Filed
Mar 17, 2023
Granted
Aug 18, 2026
Kind
B2
Art Unit
1626
USPC
544/162
Abstract

Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the following chemical structure:

Claims (7)

1 . A compound of the following formula:

wherein R 1 is C 1 -C 6 alkyl, aryl, heteroaryl, or heterocycloalkyl.

2 . A compound of claim 1 , wherein R 1 is C 1 -C 6 alkyl.

3 . A compound of claim 1 , wherein R 1 is CH 2 CH 3 .

4 . A compound of claim 1 , wherein R 1 is CH 3 .

5 . A compound of the following formula:

6 . A compound of the following formula:

Continuity (2)
Provisional Application 63321423 · Mar 18, 2022
Related Publication 20230295100A1 · Sep 21, 2023
References Cited (43)
US 3857839A · Lee · 1974 [cited by examiner]
US 4229449A · Melloni · 1980 [cited by applicant]
US 5559111A · Goschke et al. · 1996 [cited by applicant]
US 6313308B1 · Singh et al. · 2001 [cited by applicant]
US 6376711B1 · Henegar et al. · 2002 [cited by applicant]
US 6506750B1 · Ducoux et al. · 2003 [cited by applicant]
US 7501414B2 · Tornoe et al. · 2009 [cited by applicant]
US 7659394B2 · Barta et al. · 2010 [cited by applicant]
US 7994315B2 · Okuyama et al. · 2011 [cited by applicant]
US 9403783B2 · Liang · 2016 [cited by examiner]
US 10337039B2 · Trussardi et al. · 2019 [cited by applicant]
US 11634415B2 · Padia · 2023 [cited by applicant]
US 11964951B2 · Sun · 2024 [cited by examiner]
US 20110251198A1 · Liang · 2011 [cited by examiner]
US 20220306618A1 · Padia · 2022 [cited by applicant]
CA 2356299A1 · 2000 [cited by applicant]
EP 0521827A1 · 1993 [cited by applicant]
GB 1260886A · 1972 [cited by applicant]
WO WO2022198062A2 · 2022 [cited by applicant]
U.S. Appl. No. 63/162,671, filed Mar. 18, 2021, Padia, Janak Khimchand. [cited by applicant]
Howe et al., “Optical Isomers of 2-(2-Ethoxyphenoxymethyl-tetrahydro-1,4-oxazine (Viloxazine) and Related Compounds,” Journal of Medicinal Chemistry, Jan. 9, 1976, 19(8):1074-1076. [cited by applicant]
Yang et al., “Enzyme-mediated hydrolytic activation of prodrugs, Acta Pharmaceutica Sinica B,” 2011, 1(3):143-159. [cited by applicant]
Audouze et al., “New Series of Morpholine and 1,4-Oxazepane Derivatives as Dopamine D 4 Receptor Ligands: Synthesis and 3D-QSAR Model,” J. Med. Chem., 2004, 47(12):3089-3104, American Chemical Society, XP002430838. [cited by applicant]
Boot et al., “Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors,” Bioorganic & Medicinal Chemistry Letters, Feb. 1, 2005, 15(3):699-70… [cited by applicant]
Henegar, Kevin E., “Concise Synthesis of (S)-N-BOC-2-Hydroxymethylmorpholine and (S)-N-BOC-Morpholine-2-carboxylic Acid,” The Journal of Organic Chemistry, May 2008, 73(9):3662-3665. [cited by applicant]
International Search Report and Written Opinion dated Jul. 21, 2023 in PCT/US2023/015461. [cited by applicant]
Letavic et al., “2-Aryloxymethylmorpholine histamine H″3 antagonists,” Bioorganic & Medicinal Chemistry Letters, Nov. 1, 2008, 18(21):5796-5799. [cited by applicant]
Dorwald, F. Zaragoza, Side Reactions in Organic Synthesis, 2005, Wiley: VCH Weinheim Preface, pp. 1-16, 40-41 & Chapter 8, pp. 279-309 (37 pages total). [cited by applicant]
Metro et al., “Syntheses of (S,S)-Reboxetine via a Catalytic Stereospecific Rearrangement of Beta-Amino Alcohols,” The Journal of Organic Chemistry, Dec. 20, 2007, 73(2):707-710. [cited by applicant]
Aparicio et al., “Application of amide-stabilized sulfur ylide reactivity to the stereodivergent synthesis of (R, S)-and (S, R)-reboxetine,” Tetrahedron: Asymmetry, 2009, 20(23):2764-2768. [cited by applicant]
Balsamo et al., “3-[(2-Ethoxyphenoxy) methyl] piperidine derivatives. Synthesis and Antidepressant Activity,” Journal of Medicinal Chemistry, 1987, 30(1):222-225. [cited by applicant]
Breuning et al., “Efficient One-Pot Synthesis of Enantiomerically Pure 2-(Hydroxymethyl) morpholines,” European Journal of Organic Chemistry, 2007, 13:2100-2106. [cited by applicant]
Ghosh et al., “Lewis acid mediated intramolecular C—O bond formation of alkanol-epoxide leading to substituted morpholine and 1,4-oxazepane derivatives: total synthesis of (±)-Viloxazine,” Tetrahedron, 2016 (online Dec.… [cited by applicant]
Lin et al.,. “Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with positron emission tomography,” Nuclear Me… [cited by applicant]
Lin et al., “Synthesis, enantiomeric resolution, and selective C-11 methylation of a highly selective radioligand for imaging the norepinephrine transporter with positron emission tomography,” Chirality, Aug. 2004, 16(7… [cited by applicant]
Prabhakaran et al., “Chiral synthesis of (2S, 3S)-2-(2-morpholin-2-yl-2-phenylmethoxy) phenol,” Chirality, Mar. 2004, 16(3):168-173. [cited by applicant]
Steiner, Melanie, Chiral 9-Oxabispidine Design, enantioselective representation and Application in asymmetric synthesis, Doctoral dissertation, Universität Würzburg, URL: http://d-nb.info/1008731544/34, 2010, 189 pages,… [cited by applicant]
Yu et al., “The synthesis of (R, S)-reboxetine employing a tandem cyclic sulfate rearrangement—opening process,” Tetrahedron: Asymmetry, 2012, 23(9):650-654. [cited by applicant]
Zeng et al., “Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter,” Bioorganic & Medicinal Chemistry, 2008, 16(2):783-79… [cited by applicant]
Gajare et al., “A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines,” Tetrahedron Letters, 2015, 56:3743-3746. [cited by applicant]
Olofson et al., “A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine,” J. Org. Chem., Jun. 1, 1984, 49(11):2081-2082. [cited by applicant]
Pelander et al., “Preparation of N-demethylated drug metabolites for analytical purposes using 1-chloroethyl chloroformate,” Forensic Science International, Mar. 14, 1997, 85(3):193-198. [cited by applicant]
Son et al., “Dynamic Kinetic Resolution-Based Asymmetric Transfer Hydrogenation of 2-Benzoylmorpholinones and Its Use in Concise Stereoselective Synthesis of All Four Stereoisomers of the Antidepressant Reboxetine,” The… [cited by applicant]